HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Michael R Zile Selected Research

irbesartan

9/2015Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response.
8/2015Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study.
7/2015Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina: Analysis of the Irbesartan in Patients With Heart Failure and Preserved Systolic Function Trial.
6/2015Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
6/2015The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction).
1/2015International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction.
11/2014History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction.
9/2014Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment.
7/2014Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve).
9/2012Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Michael R Zile Research Topics

Disease

49Heart Failure
11/2015 - 01/2003
10Hypertrophy
12/2014 - 04/2006
9Myocardial Infarction
06/2012 - 01/2003
7Fibrosis (Cirrhosis)
11/2015 - 06/2007
7Diastolic Heart Failure
04/2014 - 04/2005
6Hypertension (High Blood Pressure)
05/2014 - 05/2006
4Cardiovascular Diseases (Cardiovascular Disease)
11/2015 - 05/2006
4Cardiomegaly (Heart Hypertrophy)
11/2015 - 01/2008
3Diabetes Mellitus
11/2014 - 02/2007
3Systolic Heart Failure
02/2014 - 09/2011
3Heart Diseases (Heart Disease)
10/2013 - 05/2006
3Ischemia
01/2008 - 12/2005
2Hypotension (Low Blood Pressure)
10/2015 - 09/2014
2Inflammation
06/2015 - 04/2015
2Unstable Angina
02/2014 - 08/2006
2Ventricular Remodeling
01/2013 - 12/2011
2Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left)
05/2011 - 02/2007
2Necrosis
01/2008 - 12/2005
1Cardiac Sudden Death (Sudden Cardiac Arrest)
08/2015
1Hyperglycemia
07/2015
1Coronary Artery Disease (Coronary Atherosclerosis)
07/2015
1Pathologic Constriction (Stenosis)
04/2015
1Left Ventricular Dysfunction
02/2015
1Anoxia (Hypoxia)
01/2015
1Hyperkalemia
09/2014
1Cough
09/2014
1Angioedema
09/2014
1Heart Arrest (Cardiac Arrest)
09/2014
1Atrial Fibrillation
07/2014
1Myocardial Ischemia (Ischemic Heart Diseases)
08/2013
1Cardiomyopathies (Cardiomyopathy)
06/2012
1Seizures (Seizure)
03/2012
1Stroke (Strokes)
03/2012
1Aortic Valve Stenosis (Aortic Stenosis)
01/2012

Drug/Important Bio-Agent (IBA)

18irbesartanFDA LinkGeneric
09/2015 - 02/2008
13Brain Natriuretic Peptide (Natrecor)FDA Link
10/2015 - 01/2011
10AngiotensinsIBA
10/2015 - 06/2007
10pro-brain natriuretic peptide (1-76)IBA
10/2015 - 05/2011
93- (1- biphenyl- 4- ylmethyl- 3- ethoxycarbonyl- 1- butylcarbamoyl)propionate- 3'- methyl- 2'- (pentanoyl(2'- (tetrazol- 5- ylate)biphenyl- 4'- ylmethyl)amino)butyrateIBA
10/2015 - 02/2014
9Matrix MetalloproteinasesIBA
08/2013 - 01/2003
8Neprilysin (Neutral Endopeptidase)IBA
10/2015 - 09/2013
7Fibrillar CollagensIBA
04/2015 - 01/2009
5CollagenIBA
04/2015 - 05/2011
5Biological Markers (Surrogate Marker)IBA
04/2015 - 12/2005
4Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA
10/2015 - 08/2006
4Tissue Inhibitor of Metalloproteinase-1IBA
04/2015 - 01/2003
4valsartan (Vals)FDA Link
11/2014 - 06/2007
4Peptide Hydrolases (Proteases)IBA
01/2013 - 05/2006
4Proteins (Proteins, Gene)IBA
01/2012 - 04/2006
3candesartanIBA
09/2015 - 01/2015
3EnalaprilFDA LinkGeneric
08/2015 - 07/2014
3Tissue Inhibitor of Metalloproteinases (TIMP)IBA
06/2012 - 01/2003
3CalciumIBA
07/2011 - 12/2005
3CalpainIBA
05/2011 - 07/2008
2MicroRNAs (MicroRNA)IBA
11/2015 - 12/2011
2Messenger RNA (mRNA)IBA
01/2015 - 01/2008
2Natriuretic PeptidesIBA
07/2014 - 09/2011
2Digoxin (Digitek)FDA LinkGeneric
02/2014 - 08/2006
2Collagen Type I (Type I Collagen)IBA
09/2011 - 01/2008
2CreatinineIBA
09/2011 - 11/2005
2OsteopontinIBA
09/2011 - 05/2011
2MCC 135IBA
01/2008 - 12/2005
1eplerenone (Inspra)FDA LinkGeneric
11/2015
1Connective Tissue Growth FactorIBA
11/2015
1Histone Deacetylases (Histone Deacetylase)IBA
11/2015
1Streptozocin (Streptozotocin)FDA Link
07/2015
1Cysteine (L-Cysteine)FDA Link
06/2015
1connectin (titin)IBA
04/2015
1C-Reactive ProteinIBA
04/2015
1glucuronyl glucosamine glycan sulfate (Vessel)IBA
04/2015
1rosuvastatin (Crestor)FDA Link
01/2015
1XCT790IBA
01/2015
1Protein Isoforms (Isoforms)IBA
01/2015
1bucindololIBA
01/2015
1OxygenIBA
01/2015
1TroponinIBA
11/2014
1Troponin T (T, Troponin)IBA
11/2014
1Trinitrotoluene (TNT)IBA
11/2014
1AldosteroneIBA
09/2014
1tilisololIBA
07/2014
1bipiperidyl mustard (BPM)IBA
07/2014
1Endothelins (Endothelin)IBA
04/2014
1sitaxsentanIBA
04/2014
1SodiumIBA
04/2014
1dihydroceramideIBA
11/2012
1Myristic Acid (Tetradecanoic Acid)IBA
11/2012
1dihydroceramide desaturaseIBA
11/2012
1ProcollagenIBA
11/2012
1Matrix Metalloproteinase 14 (MT1-MMP)IBA
04/2012
1AdenosineFDA LinkGeneric
03/2012
11,3-dipropyl-8-(3-noradamantyl)xanthineIBA
03/2012
1platelet-derived growth factor AIBA
01/2012
1platelet-derived growth factor BB (becaplermin)FDA Link
01/2012
1Fibronectins (Fibronectin)IBA
01/2012
1Collagen Type III (Type III Collagen)IBA
09/2011

Therapy/Procedure

1Cardiac Resynchronization Therapy
10/2015
1Patient Readmission
07/2015
1Investigational Therapies (Experimental Therapy)
02/2015
1Sympathectomy (Sympathectomies)
05/2014
1Activities of Daily Living (ADL)
05/2013